1-pentyl-1,2,3,4-tetrahydroisoquinoline | 1189162-52-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 1-pentyl-1,2,3,4-tetrahydroisoquinoline
• CAS: 1189162-52-4
• 化学式: C₁₄H₂₁N
• 分子量: 203.327
• InChiKey: PIKCMDMGVQSKGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-pentyl-1,2,3,4-tetrahydroisoquinoline 在 氯磺酰异氰酸酯 、 三乙胺 作用下， 以 二氯甲烷 、 叔丁醇 为溶剂， 反应 1.5h， 以58%的产率得到1-pentyl-1,2,3,4-tetrahydroisoquinoline-2-sulfonamide
  参考文献：
  名称：

  通过自由基易位的2-烷基氮杂氮杂环化合物的区域选择性侧链胺化：四皂素T8的全合成

  摘要：

  据报道，饱和的2-烷基氮杂环的侧链具有区域选择性的γ-CH胺化反应，该过程通过磺酰胺定向的1,6-自由基易位进行。生物碱四皂甙T8和非天然类似物的简短合成突显了这种快速获取1,3-二胺的实用性。

  DOI：

  10.1039/d0cc07625b
• 作为产物：
  描述：

  N-formyl-1-N-pentyl-1,2,3,4-tetrahydroisoquinoline 在 乙醇 、 sodium hydroxide 作用下， 反应 3.0h， 以90%的产率得到1-pentyl-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Facile synthesis and in vitro properties of 1-alkyl- and 1-alkyl-N-propargyl-1,2,3,4-tetrahydroisoquinoline derivatives on PC12 cells

  摘要：

  The synthesis of several 1-alkyl-1,2,3,4-tetrahydroisoquinolines, which may play an important role in Parkinson's disease, has been achieved by modified Pictet-Spengler cyclization of the formyliminium ion. The direct cytotoxicity and preventative effects towards MPP+-mediated death of PC12 cells were estimated. The cytotoxicities of 1-alkyl-TIQs were apoptotic and depended on their lipophilic properties. Conversely, introducing the N-propargyl substituent reduced cytotoxicity. 1-Methyl-, 1-methyl-N-propargyl- and 1-cyclopropyl-TIQ partially inhibited MPP+-induced cell death, whereas relatively large alkyl substituents at the first position did not enhance the viability of PC12 cells. In summary, our findings suggest a crucial role for the N-propargyl functional group for the effective reduction of cytotoxicity, and show the importance of size and lipophilicity of substituents at the 1-position of 1-alkyl TIQs. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.04.035

文献信息

• Synthesis of Tetrahydroisoquinoline Alkaloids and Related Compounds through the Alkylation of Anodically Prepared α-Amino Nitriles
  作者：Lotfi Benmekhbi、Fadila Louafi、Thierry Roisnel、Jean-Pierre Hurvois

  DOI：10.1021/acs.joc.6b01419

  日期：2016.8.5

  α-Amino nitrile 2a was conveniently prepared in two individual steps from chiral hexafluorophosphate salt isoquinolinium (−)-8b including anodic cyanation as an efficient means to activate the sp3 C1–H bond of the THIQ nucleus. The lithiation of 2a was carried out in THF at −80 °C in the presence of LDA to produce a stable α-amino carbanion which was condensed on a large variety of alkyl halides. The

  α-氨基腈2a可以方便地在两个独立的步骤中从手性六氟磷酸盐异喹啉鎓（-）- 8b制备，包括阳极氰化作为激活THIQ核的sp 3 C1-H键的有效方法。2a的锂化反应是在LDA的存在下于-80°C的THF中于-80°C进行的，以生成稳定的α-氨基碳负离子，将其冷凝在多种烷基卤上。在作为氢化物供体的NaBH 4存在下，在乙醇中对所得的季α-氨基腈进行立体选择性还原脱氰反应，生成N -Boc-1-烷基-THIQs（+）- 10a – g除去手性辅助基团后最多可达到97：3 er。对THIQ（+）- 1f的ORTEP视图的检查表明，新创建的立体生成中心具有绝对的S构型。同样地，在四个后处理步骤中，从α-氨基腈（+）- 2b以63％的总收率合成了（-）-xylopinine 。在此过程中，将对映浓缩的（-）-去甲月桂花碱与1当量的（-）- N-乙酰基-1-亮氨酸的混合物（90:10）结晶，得到亮氨酸盐（+）-
• [EN] ACYL ISOINDOLINE DERIVATIVES AND ACYL ISOQUINOLINE DERIVATIVES AS ANTI-VIRAL AGENTS<br/>[FR] DERIVES D'ACYLE ISOINDOLINE ET D'ACYLE ISOQUINOLINE UTILISES COMME AGENTS ANTIVIRAUX
  申请人：GLAXO GROUP LTD

  公开号：WO2004096774A1

  公开（公告）日：2004-11-11

  Anti-viral agents of Formula (I) wherein: R3 represents aryl or heteroaryl; R4 represents one or two substituents independently selected from hydrogen, C 1-6alkyl, halo, ORA , C(O)NRBRC, C(O)RD, CO2H, CO2RD, NRBRC, NRE C(O)RD, NRECO2RD, NREC(O)NRFRG, NRESO2RD, SO2NRFRG, SO2RD, nitro, cyano, heterocyclyl, heteroaryl, aryl, arylalkyl heteroarylalkyl or CF3; R5 and R6 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; n represents 0 or 1; when n represents 0, R1 represents C(O)RH and R2 represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; when n represents 1, either i) R1 represents C(O)RH; R2 represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; and R7 and R8 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; or ii) R1 and R2 independently represent hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; R7 represents C(O)RH; and R8 represents C1-6alkyl, heterocyclylalkyl, arylalkyl or heteroarylalkyl; RA represents hydrogen, C1-6alkyl, arylalkyl, heteroarylalkyl, aryl or heteroaryl; RB and RC independently represent hydrogen, C1-6alkyl, aryl or heteroaryl; or RB and RC together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; RD is selected from the group consisting of C1-6alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; RE represents hydrogen or C1-6alkyl; RF and RG are independently selected from the group consisting of hydrogen, C1-6alkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl; or RF and RG together with the nitrogen atom to which they are attached form a 5 or 6 membered saturated cyclic group; RH represents hydroxy or NRBRC; and salts, solvates and esters thereof; provided that when RH is hydroxy, which is esterified to form -OR where R is selected from straight or branched chain alkyl, aralkyl, aryloxyalkyl, or aryl, then R is other than tert-butyl. Processes for their preparation and methods of using them in HCV treatment are provided.

  Formula（I）的抗病毒剂，其中：R3代表芳基或杂环芳基；R4代表一个或两个取代基，独立选择自氢、C1-6烷基、卤素、ORA、C（O）NRBRC、C（O）RD、CO2H、CO2RD、NRBRC、NREC（O）RD、NRECO2RD、NREC（O）NRFRG、NRESO2RD、SO2NRFRG、SO2RD、硝基、氰基、杂环烷基、杂环芳基、芳基、芳基烷基、杂环芳基烷基或CF3；R5和R6独立代表氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；n代表0或1；当n代表0时，R1代表C（O）RH，R2代表C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；当n代表1时，要么i）R1代表C（O）RH；R2代表C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；且R7和R8独立代表氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；或ii）R1和R2独立代表氢、C1-6烷基、芳基、杂环芳基、芳基烷基或杂环芳基烷基；R7代表C（O）RH；且R8代表C1-6烷基、杂环烷基、芳基烷基或杂环芳基烷基；RA代表氢、C1-6烷基、芳基烷基、杂环芳基烷基、芳基或杂环芳基；RB和RC独立代表氢、C1-6烷基、芳基或杂环芳基；或RB和RC与它们连接的氮原子一起形成5或6个成员饱和环；RD选自由C1-6烷基、芳基、杂环芳基、芳基烷基和杂环芳基烷基组成的群体；RE代表氢或C1-6烷基；RF和RG独立选择自氢、C1-6烷基、芳基、杂环芳基、芳基烷基和杂环芳基烷基组成的群体；或RF和RG与它们连接的氮原子一起形成5或6个成员饱和环；RH代表羟基或NRBRC；以及其盐、溶剂化合物和酯；但是当RH是羟基时，酯化形成-OR，其中R选择自直链或支链烷基、芳基烷基、芳氧基烷基或芳基，那么R不是叔丁基。提供了它们的制备方法以及在HCV治疗中使用它们的方法。
• [EN] 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO[2,1-B]-QUINAZOLINONE DERIVATIVES<br/>[FR] DERIVES DE 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO ET 2,3-DIHYDRO-2H-PYRROLO[2,1-B]-QUINAZOLINONE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2004004733A1

  公开（公告）日：2004-01-15

  The invention relates to novel 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2H-pyrrolo[2,1-b]-quinazolinone derivatives of formula (I) and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as orexin receptor antagonists.

  本发明涉及一种新型的7,8,9,10-四氢-6H-氮杂七环、6,7,8,9-四氢-吡啶和2,3-二氢-2H-吡咯并[2,1-b]-喹唑啉衍生物(I式)，以及它们作为制备药物组分的活性成分的用途。本发明还涉及相关方面，包括制备化合物的过程、含有这些化合物中的一个或多个的药物组合物，特别是它们作为促进睡眠的药物组分的用途。
• 光学活性１−アリール−１，２，３，４−テトラヒドロイソキノリン類の製造法
  申请人：——

  公开号：JP2001026580A

  公开（公告）日：2001-01-30

  (57)【要約】\n【課題】 光学活性１-アリール−１,2,3,4−テトラヒドロイソキノリン類の製造法を提供すること。\n【解決手段】 一般式（１）\nで示される１-アリール−3,4−ジヒドロイソキノリン類を、第VIII族遷移金属の錯体、光学活性ホスフィン化合物の存在下に、水素と反応させることを特徴とする一般式（２）\nで示される光学活性１-アリール−１,2,3,4−テトラヒドロイソキノリン 類の製造法。

  (57) [摘要] Јn [问题] 提供一种生产光学活性 1-芳基-1,2,3,4-四氢异喹啉的方法。\解] 通式（1）Јn 所示的 1-芳基-3,4-二氢异喹啉在第八族过渡金属和光学活性膦化合物的络合物存在下与氢反应。一种生产光学活性 1-芳基-1,2,3,4-四氢异喹啉的方法。
• 7,8,9,10-TETRAHYDRO-6H-AZEPINO, 6,7,8,9-TETRAHYDRO-PYRIDO AND 2,3-DIHYDRO-2H-PYRROLO (2,1-B)-QUINAZOLINONE DERIVATIVES
  申请人：Actelion Pharmaceuticals Ltd.

  公开号：EP1521583A1

  公开（公告）日：2005-04-13